Free Trial
NASDAQ:TSBX

Turnstone Biologics Q1 2024 Earnings Report

Turnstone Biologics logo
$0.34 -0.02 (-5.56%)
Closing price 04:00 PM Eastern
Extended Trading
$0.35 +0.01 (+1.76%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Turnstone Biologics EPS Results

Actual EPS
-$0.85
Consensus EPS
-$0.78
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Turnstone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Turnstone Biologics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Turnstone Biologics' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Turnstone Biologics Earnings Headlines

Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
Trump Orders 'National Digital Asset Stockpile'
Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fuse. We're entering a new phase where economic uncertainty and technological transformation collide — and blockchain adoption is gaining steam from the highest levels of finance. Amid this shift, I've zeroed in on one standout coin.
See More Turnstone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Turnstone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Turnstone Biologics and other key companies, straight to your email.

About Turnstone Biologics

Turnstone Biologics (NASDAQ:TSBX), a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

View Turnstone Biologics Profile

More Earnings Resources from MarketBeat